92 results about "Dysbiosis" patented technology

There are provided novel synthetic stool preparations comprising bacteria isolated from a fecal sample from a healthy donor. The synthetic stool preparations are used for treating disorders of the gastrointestinal tract, including dysbiosis, Clostridium difficile infection and recurrent Clostridium difficile infection, prevention of recurrence of Clostridium difficile infection, treatment of Crohn's disease, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, and diverticular disease, and treatment of food poisoning such as salmonella. Methods of preparation and methods of use of the synthetic stool preparations are also provided.

A dietary supplement that may contain probiotics from the genera Akkermansia, Bacteriodes, Faecalibacterium, Eubacterium, Escherichia, Collinsella, Desulfovibrio, Clostridium, Mycobacterium, Pediococcus, and Bifidobacterium. The dietary supplement may provide a variety of benefits including weight management, blood sugar management, treatment of irritable bowel syndrome, treatment of Crohn's disease, treatment of diverticulitis, treatment for inflammatory bowel, treatment for dysbiosis, and strengthening the immune system.

A probiotic composition used for livestock and poultry can overcome micro dysbiosis, decreased disease resistance and production performance of livestock and poultry, and the side effects like drug resistance and drug residue which are caused by using antibiotics and chemical drugs in a large amount for a long time in feed. The probiotic composition contains effective components with the following weight portions: 3 to 10 portions of Lactobacillus acidophilus, 2 to 6 portions of yeast, 1 to 8 portions of bacillus subtilis, 3 to 8 portions of Bifidobacterium longum, 2 to 5 portions of bacillus licheniformis, and 1 to 4 portions of aspergillus oryzae and vector. The weight ratio of probiotic to vector is 2:7, and the content of the active compositions are that: greater than or equal to 8 billion / g of Lactobacillus acidophilus, greater than or equal to 7 billion / g of yeast, greater than or equal to 9 billion / g of bacillus subtilis, greater than or equal to 9 billion / g of Bifidobacterium longum, greater than or equal to 6 billion / g of bacillus licheniformis and greater than or equal to 6 billion / g of aspergillus oryzae, respectively. The probiotic composition of the invention can reduce lead content in animal products, achieve the purpose of producing green and harmless animal products, promote growth and development of animal and increase animal digestibility to feed.

Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

The present invention is directed to a method of treating a dysbiosis in a mammal, preferably a human, by taking a sample of the micro-organisms that are causative of the dysbiosis, whereafter said sample is enriched in vitro for healthy bacteria, after which the sample is replaced.

Provided are therapeutic compositions containing ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

The present invention relates to the use of type 2 cytokines and mucins for increasing the amount or activity of bacterial species of the Clostridia class in the gastrointestinal tract, for treating dysbiosis in the gastrointestinal tract, for treating gastrointestinal and inflammatory disorders, and for promoting wound healing in the gastrointestinal tract.

The present invention relates to a kind of composition containing plant lactobacillus LP-Onlly strain and its application in strengthening intestinal immunobarrier. The composition of the present invention can intervene the homing of intestinal lymphocyte, control the number of intestinal tract secretive IgA and intestinal lymphocyte, lower the endotoxin level, improve intestinal tract immunobarrier and prevent damage of intestinal tract immunobarrier caused by hunger, malnutrition, infection, etc, and prevent and treat intestinal inflammation, infectious diseases and immune disorder diseases.

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).

Various types of synbiotic therapies are provided for the treatment of a variety of gastrointestinal and other disorders. The combination of prebiotics to probiotics is defined as a synbiotic therapy. The principal GI disorders associated with dysbiosis that can be treated from such a therapeutic intervention include but are not limited to: inflammatory bowel disease (IBD) (Crohn's disease and ulcerative colitis), irritable bowel syndrome (IBS), antibiotic-associated diarrheas such as recurrent Clostridium difficile infection, and possibly variants of Celiac disease. Other disorders that may also be ameliorated by the proposed synbiotic therapy include metabolic syndromes and central nervous system disorders. The disclosed methods and compositions were developed to improve upon currently available probiotics through consideration of the human intestinal microbiota, and its relationship to various intestinal metabolic and neuropsychiatric disorders. In one embodiment, the disclosed synbiotic compositions include prebiotics and a targeted delivery system, which altogether promote the survival, growth, and attachment of probiotic microbiota.

Methods and compositions for controlling termite populations by leveraging newly discovered mechanisms for symbiont- and host mediated anti-fungal defenses in the termite hind-gut. Such methods may include administering a composition to a termite, the composition formulated to promote protist dysbiosis in the gut of the termite, or silencing specific host or symbiont genes by RNA interference, and exposing the termite to a pathogen, where the composition increases the susceptibility of the termite to the pathogen. Compositions are also provided for the treatment of fungal infections, the composition comprising a medically effective amount of recombinant glycosyl hydrolase family 7 cellulase, as well as methods for utilizing the same.

Compositions and methods of treating a gastrointestinal dysbiosis using a limited number of defined bacterial species are provided.

This document relates to biomarkers of gut microbiota dysbiosis. Bacteria that are increased or decreased in gut microbiota dysbiosis can be used as biomarkers to predict dysbiosis in patients with diarrhea and / or to predict susceptibility to Clostridium difficile infection (CDI). In addition, provided herein are compositions including at least three bacteria that are de creased in gut microbiota dysbiosis which can be used, for example, to restore heathy gut microbiota (e.g., by probiotic or by fecal microbiota transplant) to treat CDI.

Described herein are methods and compositions for the treatment of skin conditions associated the dysbiosis. Further described herein is the use of metabolites for treatment of dysregulated microbiota in a subject. Such metabolites can be produced by microorganisms present in a higher abundance in the skin of healthy subjects as compared to the skin of a subject having dysbiosis of the skin. In addition, compositions and methods provided herein describe the use of metabolites as part of a combination therapy.

Various types of synbiotic therapies are provided for the treatment of a variety of gastrointestinal and other disorders. The combination of prebiotics to probiotics is defined as a synbiotic therapy. The principal GI disorders associated with dysbiosis that can be treated from such a therapeutic intervention include but are not limited to: inflammatory bowel disease (IBD) (Crohn's disease and ulcerative colitis), irritable bowel syndrome (IBS), antibiotic-associated diarrheas such as recurrent Clostridium difficile infection, and possibly variants of Celiac disease. Other disorders that may also be ameliorated by the proposed synbiotic therapy include metabolic syndromes and central nervous system disorders. The disclosed methods and compositions were developed to improve upon currently available probiotics through consideration of the human intestinal microbiota, and its relationship to various intestinal metabolic and neuropsychiatric disorders. In one embodiment, the disclosed synbiotic compositions include prebiotics and a targeted delivery system, which altogether promote the survival, growth, and attachment of probiotic microbiota.

The present invention provides a method of increasing the growth of staphylococcus epidermidis on skin, comprising topically applying to skin in need of treatment for eczema, acne, decreased moisturization, or other skin conditions associated with microbiota dysbiosis a composition comprising an extract of Pichia anomala and glycerin.

The present invention provides compositions of therapeutic agents and methods of use for reducing and / or treating gastrointestinal inflammation. In particular aspects, the tungstate salts described herein and pharmaceutical compositions thereof inhibit the activity of one or a plurality of anaerobic respiratory enzymes in facultative anaerobic bacteria such as, for example, Enterobacteriaceae, that can exacerbate inflammation. In particular embodiments, the present invention provides compositions of therapeutic agents for treating gastrointestinal inflammation, as well as methods for treating or preventing gut microbial imbalance due to an increase in the abundance of intestinal Enterobacteriaceae.

The present invention relates to compositions and their use for oral care. In particular, the compositions and methods are for maintaining oral health and / or treating various oral conditions such as gingivitis. The present invention relates to methods and uses of stabilized amorphous calcium phosphate (ACP) and / or stabilized amorphous calcium fluoride phosphate (ACFP) in the preparation of a medicament for reducing pathogenic oral bacteria at an oral site in an individual; increasing commensal oral bacteria at an oral site in an individual; decreasing the proportion of pathogenic oral bacteria at an oral site in an individual; inhibiting oral dysbiosis; reducing gingival inflammation in an individual in need thereof; treating gingivitis in an individual in need thereof; and treating chronic gingivitis in an individual in need thereof.

The present invention relates to agents and compositions for the modification of the growth of bacterial cells. Thus, the compounds of the present invention are useful for the prevention and / or treatment of a disease in a subject. In particular, the present invention relates to the field of repurposing pharmaceutical compounds for treatment strategies of infectious diseases, gastrointestinal disorders, inflammatory diseases, proliferative diseases, metabolic disorders, cardiovascular diseases, and immunological diseases. Some of the compounds of the present invention demonstrate high specificity in inhibiting the growth of single bacterial species. Such compounds enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development strategies in order to reduce side effects of antibacterial treatment plans. Particularly interesting compounds of this invention are effective against pathobiological species such as Clostridium difficile, Clostridium perfingens, Fusobacterium nucleatum, and an enterotoxigenic strain of Bacteroides fragilis. Other compounds of the present invention reveal a strong inhibitory effect on a broad spectrum of bacterial species. Such compounds are useful for broad-spectrum antibiotic therapies of infections with unknown causative infecting bacterial species. Both types of compounds, especially the ones with narrow-spectrum antibacterialactivity, can further be used for modulating the microbiome composition and targeting species associated with dysbiosis and disease.

The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide for use in preventing and / or treating non-rotavirus diarrhea in infants or young childrenby acting on the dysbiosis of the microbiota preceding and / or following the non-rotavirus diarrhea. The composition can be an infant formula and is in particular intended for infants between 0 and 12 months of age fed predominantly with infant formula. It promotes a healthy intestinal flora and has beneficial short and long terms effects.

The invention discloses toothpaste for children and a preparation method thereof. A compound of lysozyme, fructo-oligosaccharide and rice germ extract is added into the toothpaste, so that the quantity of oral pathogenic bacteria such as streptococcus mutans, porphyromonas gingivalis, staphylococcus aureus, escherichia coli, candida albicans and prevotella intermedia can be obviously reduced, andthe oral microenvironment is improved; meanwhile, the toothpaste has the remarkable proliferation promoting effect on intestinal beneficial bacteria such as bifidobacteria and lactic acid bacteria; and a toothpaste matrix is safe in material selection, so that even if the toothpaste is swallowed accidentally, no adverse effect is caused to the bodies of the children. The toothpaste solves the problems that toothpaste products containing chemical antibacterial components easily cause dysbiosis of oral bacteria, enable the bacteria to generate drug resistance and cannot achieve the effect of preventing oral diseases, is not added with chemical medicine components, does not contain fluorine, can better care the body health of the children, and enables the bodies of the children to develop healthily and well.

Methods for treating and preventing dysbiosis in a subject suffering from or susceptible to gastrointestinal disorders are described. The methods comprises administering a hyperimmunized egg product to the subject, wherein the egg product is obtained from a hyperimmunized avian, optionally in combination with an additional compound such as a probiotic and / or nutrient source.

Compositions and methods of treating a gastrointestinal dysbiosis using a limited number of defined bacterial species are provided.

Described herein are methods and compositions for the treatment of skin conditions associated with dysbiosis. Skin conditions associated with dysbiosis for treatment using compositions and methods described herein include atopic dermatitis, eczema, dermatitis, psoriasis, rosacea, and acne. Compositions include single or more than one strain of healthy donor derived bacteria for administration to provide therapy for skin conditions associated with dysregulated microbiota. Such compositions include gram negative and / or gram positive bacteria.

The present invention provides a hard capsule comprising an outer and one inner capsule, wherein the outer capsule comprises a hydrophobic liquid and the inner capsule which comprises a composition comprising uncoated microorganisms and optionally at least one desiccant. The composition may comprise a filtrate composed of viable fecal bacteria useful forfecal microbiota transplantation (FMT) or a mixture of one or more different types of microorganisms isolated from intestinal microbiome, such as bacteria, archaea, virus, or fungi such as yeast. The composition may comprise a desiccant, preferably a food approved component which is degradable in the gastrointestinal tract. The hydrophobic liquid, if present, is preferably at least one edible oil. Also provided are methods of treating or preventing a dysbiosis in a human subject, comprising administering to the human subject at least one capsule of the invention.

The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide for use in preventing and / or treating non-rotavirus diarrhea in infants or young children by acting on the dysbiosis of the microbiota preceding and / or following the non-rotavirus diarrhea. The composition can be an infant formula and is in particular intended for infants between 0 and 12 months of age fed predominantly with infant formula. It promotes a healthy intestinal flora and has beneficial short and long terms effects.

Some embodiments of the invention include a composition and method for treating dysbiosis in infants. The composition may include a mixture of activated bifidobacteria and a complex oligosaccharide wherein the complex oligosaccharide may be derived from a human or non-human source.

A probiotic composition used for livestock and poultry can overcome micro dysbiosis, decreased disease resistance and production performance of livestock and poultry, and the side effects like drug resistance and drug residue which are caused by using antibiotics and chemical drugs in a large amount for a long time in feed. The probiotic composition contains effective components with the following weight portions: 3 to 10 portions of Lactobacillus acidophilus, 2 to 6 portions of yeast, 1 to 8 portions of bacillus subtilis, 3 to 8 portions of Bifidobacterium longum, 2 to 5 portions of bacilluslicheniformis, and 1 to 4 portions of aspergillus oryzae and vector. The weight ratio of probiotic to vector is 2:7, and the content of the active compositions are that: greater than or equal to 8 billion / g of Lactobacillus acidophilus, greater than or equal to 7 billion / g of yeast, greater than or equal to 9 billion / g of bacillus subtilis, greater than or equal to 9 billion / g of Bifidobacterium longum, greater than or equal to 6 billion / g of bacillus licheniformis and greater than or equal to 6 billion / g of aspergillus oryzae, respectively. The probiotic composition of the invention can reduce lead content in animal products, achieve the purpose of producing green and harmless animal products, promote growth and development of animal and increase animal digestibility to feed.

Provided herein are methods for decreasing dysbiosis, restoring the microbiome, and / or increasing recovery of a healthy microbiome ( e.g. following a dysbiosis inducing event), by administering pharmaceutical compositions to a subject. Also provided are methods for protecting the microbiome of a subject and / or colonizing the microbiome of a subject by administering pharmaceutical compositions to the subject.